Intravenous (IV) Hydration Therapy Top Companies-Recent Developments, Business Strategy, Deal Strategy, Patent Strategy, Benchmarking and Management Outlook
Date : November 2024
Intravenous (IV) Hydration Therapy Market Size Analysis and Top Companies
The global intravenous (IV) hydration therapy market size is estimated to hit around USD 5.41 billion by 2033, increasing from USD 2.51 billion in 2023 with a CAGR of 7.98% from 2023 to 2033.The top companies operating in the intravenous (IV) hydration therapy market are Core IV Therapy, LLC, Otsuka Pharmaceutical Co., Ltd., Baxter International Inc., Drip Hydration, NexGen Health, JW Life Science Corporation, Amanta Healthcare, Cryojuvenate UK Ltd., B. Braun Medical Inc., and Others.
Market Report Coverage
| Report Coverage | Details |
| Market Size by 2033 | USD 5.41 Billion |
| Market Size in 2023 | USD 2.51 Billion |
| Market Growth Rate from 2023 to 2033 | CAGR of 7.98% |
| Largest Market | North America |
| Base Year | 2023 |
| Forecast Period | 2023 to 2033 |
| Segments Covered | Service, Component, End-Use, and Regions |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America and Middle East, & Africa |
Intravenous (IV) Hydration Therapy Key Players
- Core IV Therapy, LLC
- Otsuka Pharmaceutical Co., Ltd.
- Baxter International Inc.
- Drip Hydration
- NexGen Health
- JW Life Science Corporation
- Amanta Healthcare
- Cryojuvenate UK Ltd.
- B. Braun Medical Inc.
Recent Developments
- In June 2024, ChromaDex unveiled Niagen+, a pharmaceutical-grade injectable and intravenous version of Niagen, the business's proprietary nicotinamide riboside (NR) NAD+ precursor.
- In April 2024, the intravenous (IV) infusion formulation of Fycompa (perampanel hydrate), an antiepileptic medication (AED) that Eisai Co., Ltd. developed in-house, was introduced in Japan.
- In May 2022, according to Roche Pharma, the world's first fixed-dose formulation of two monoclonal antibodies for the treatment of cancer, PHESGO, was launched in India.
Hydration Therapy Market Major Announcements
To establish a new company specializing in cutting-edge technology for the treatment of cardiac arrhythmias, Adagio Medical has announced the conclusion of its business combination with ARYA Sciences Acquisition Corp IV, a special-purpose acquisition company supported by an affiliate of Perceptive Advisors.
We have prepared a service to support you. please feel free to contact us at sales@precedenceresearch.com | +1 804 441 9344
Keypoints
- Company Overview
- Locations & Subsidiaries/Geographic reach
- Key Executives
- Company Financials
- Patents registered
- SWOT Analysis
- Corporate Strategy
- Applications Catered
- Strategic collaborations
- Recent Developments
- Competitive Benchmarking